XKDCT293 (Nectin-4-CAR-T)

Nectin-4-targeted CAR-T therapy · Shenzhen Celconta Life Science Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for XKDCT293 (Nectin-4-CAR-T), covering 2024-12-09 to 2024-12-09. Get the full timeline:

Most recent: Clinical Trial Update: Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T) [Phase 1]